JSPR
Jasper Therapeutics, Inc.
$0.93
+1.97%
2026-05-08
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Key Fundamentals
Forward P/E
-0.56
EPS (TTM)
$-3.95
ROE
-230.3%
Profit Margin
0.0%
Debt/Equity
29.75
Price/Book
6.35
Beta
3.08
Market Cap
$26.3M
Avg Volume (10D)
248K
Recent Breakout Signals
No recent breakout signals detected for JSPR.
Recent Price Range (60 Days)
60D High
$1.45
60D Low
$0.63
Avg Volume
427K
Latest Close
$0.93
Get breakout alerts for JSPR
Sign up for Breakout Scanner to receive daily notifications when JSPR triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Jasper Therapeutics, Inc. (JSPR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors JSPR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. JSPR operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.